Therapeutic or Preventive Procedure – Page 2

Neuphoria’s Social Anxiety Drug Fails in Phase 3 Trial, Program Discontinued

6 days ago talkbio0Tagged AFFIRM-1, BNC210, Clinical Failure, Neuphoria, Phobia, Social, Post-Traumatic Stress Disorder, strategic review

Neuphoria Therapeutics; BNC210; social anxiety disorder; phase 3 trial; AFFIRM-1; clinical failure; strategic review; PTSD

Companies Struggle to Accelerate Production of Bespoke mRNA Therapies

6 days ago talkbio0Tagged bespoke, Cancer Vaccines, cold chain logistics, Efficiency, innovation, Manufacturing, manufacturing challenges, mRNA production, mRNA therapies, Optimization, Precision Medicine, regulatory complexity, scalability

bespoke mRNA therapies; personalized medicine; manufacturing challenges; cancer vaccines; scalability; manufacturing efficiency; cold chain logistics; regulatory complexity; mRNA production innovation; AI optimization

Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress

6 days ago talkbio0Tagged biofilm-driven chronic respiratory disease, Brendan Doran, Clarametyx Biosciences, corporate development, executive promotions, Leadership, pipeline development, Steve St. Onge, Team

Clarametyx Biosciences; leadership team; executive promotions; pipeline development; corporate development; Steve St. Onge; Brendan Doran; immune-enabling therapies; biofilm-driven chronic respiratory disease

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

7 days ago talkbio0Tagged Biotechnology, board of directors, Clinical Development, Dimitri Azar, Diorasis, gene therapy, Glaucoma, Ophthalmology specialty, United States Food and Drug Administration

Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development

Recent Advances and News in In Vivo Therapeutic Technologies (2025)

1 week ago talkbio0Tagged Acquisitions, Autoimmune Diseases, CAR-T, Cell Therapy, drug delivery innovation, Fast Track, gene therapy, in vivo, nanoparticle delivery, Neoplasms, RNA delivery, United States Food and Drug Administration

in vivo CAR-T; cell therapy; gene therapy; RNA delivery; autoimmune disease; oncology; nanoparticle delivery; drug delivery innovation; FDA fast track; biotech acquisitions

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

1 week ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

1 week ago talkbio0Tagged AstraZeneca, drug price, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Glucagon-Like Peptide 1, Medicaid, Most-Favored-Nation, Pfizer, Pricing, serono, Trump administration, United States Food and Drug Administration, Voucher

most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

1 week ago talkbio0Tagged Autoimmune Diseases, Celiac Disease, Diabetes Mellitus, Insulin-Dependent, EVOQ, Immune Tolerance, License Agreement, Lupus Vulgaris, MOG antibody disease, NanoDisc, Rheumatoid Arthritis, sanofi

Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for Neurotrophic Keratitis

2 weeks ago talkbio0Tagged gene therapy, HSV-1 viral vector, KB801, Krystal Biotech, Neurotrophic keratitis, platform technology designation, redesable eye drop, United States Food and Drug Administration, VYJUVEK

Krystal Biotech; FDA; platform technology designation; HSV-1 viral vector; KB801; gene therapy; neurotrophic keratitis; redesable eye drop; VYJUVEK

Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale

2 weeks ago talkbio0Tagged AimedBio, Antibody-Drug Conjugates, Biopharma, Boehringer Ingelheim, Cancer Therapeutic Procedure, EyePoint, Funding, Licensing, stock sale, therapeutic autologous dendritic cells

Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding